Abstract
It has been proposed for several decades that angiogenesis is an intrinsic part of tumor development and progression (1). Vice versa, inhibition of tumor angiogenesis might be a therapeutic approach to treat malignant tumors (ref. 2, for review see ref. 3). These hypotheses are based on the following observations: (i) tumor cells are able to secrete endothelial cell growth factors and to induce angiogenesis in in vivo test systems such as the chorioallantoic membrane assay (1), (ii) malignant tumors are consistently better vascularized than their benign counterparts or precursor lesions (a phenomenon which has been described as a “switch to the angiogenic state,” ref. 4), and (iii) several compounds that have been shown to inhibit endothelial cell proliferation in vitro, inhibited tumor growth in vivo (for review see ref. 5).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Folkman J, 1990; What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (82): 4–6
Gimbrone M.A, Jr., Leapman S B, Cotran R S, Folkman J, 1972; Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136: 261–276
Folkman J, Hanahan D, 1991; Expression of the angiogenic phenotype during development of murine and human cancer. In: Origins of human cancer: A comprehensive review. Cold Spring Harbor Laboratory Press, pp 803–814
Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364, 1996
Moses MA, Langer R. Inhibitors of angiogenesis. Biotechnology 9: 630–634 (1991)
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S. Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhard, C., Desclerc, C., Pawling, M., Moons, L., Collen, D., Risau, W., and Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435–439, 1996
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O’Shea, K.S., Powell-Braxton, L., Hillan, K., and Moore, M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439–442, 1996
Fong G-H, Rossant J, Gertsenstein M, Breitman ML: Role of the fit-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66–70, 1995
Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu X-F, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in flk-1 deficient mice. Nature 376: 62–66, 1995
Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Quin Y (1995) Distinct roles of the receptor tyrosine kinases tie-1 and tie-2 in blood vessel formation. Nature 376: 70–74
Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato N, Yancopoulos G. Requisite role of angiopoietin-1, a ligand for the tie2 receptor, during embryonic angiogenesis. Cell 87: 1171–1180, 1996
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich T, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopoietin-2, a natural antagonist for tie2 that disrupts in vivo angiogenesis. Science 277: 55–60, 1997
Plate KH, Breier G, Risau W (1994) Molecular mechanisms of developmental and tumour angiogenesis. Brain Pathol 4: 207–218
Plate KH, Risau W. Angiogenesis in malignant gliomas. Glia 15: 339–347, 1995
Breier G, Damert A, Plate KH, Risau W. Angiogenesis in embryos and ischemic diseases. Thrombosis and Haemostasis 78: 678–683 (1997)
Plate KH. Gene therapy of malignant glioma via inhibition of tumor angiogenesis. Cancer & Metastasis Reviews 15: 237–240 (1996)
Leung DW, Cachianes G, Kuang W-J, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306–1309, 1989
Conolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470–1478, 1989
Keck PJ, Hauser S, Krivi G, Sanzo K, Warren T, Feder J, Conolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (246): 1309–1312, 1989
Alon T, Hemo I, Itin A, Peér J, Stone J, Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Medicine (1):1024–1028, 1995
Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 94: 8761–8766, 1997
Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845–848, 1992
Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843–845, 1992
Ikeda E, Achen MG, Breier G, Risau W: Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270:19761–19766, 1995
Levy, A.P., Levy, N.S., and Goldberg, M.A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 271: 2746–2753, 1996
Damert A, Machein M, Breier G, Fujita MQ, Hanahan D, Risau W, Plate KH. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Research 57: 3860–3864, 1997
De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams, LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989–991, 1992
Terman BC, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bšhlen P: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Comm 187: 1579–1586, 1992
Millauer B, Wizigmann-Voos S, SchnŸrch H, Martinez R, Moller NPH, Risau W, Ullrich A: High affinity VEGF binding and developmental expression suggests flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835–846, 1993
Plate KH, Breier G, Weich HA, Mennel HD, Risau W: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int. J Cancer 59:520–529, 1994
Kremer C, Breier G, Risau W, Plate KH. Upregulation of flk-1/VEGF receptor-2 by its ligand in a cerebral slice culture system. Cancer Research 57: 3852–3859, 1997
Stratmann A, Machein MR, Plate KH. Anti-angiogenic gene therapy of malignant gliomas. Acta Neurochirugica, Suppl. 68:105–110, 1997
Kim JB, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841–844, 1993
Kondo S, Asano M, Suzuki H (1993) Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Comm 194: 1234–1241
Millauer B, Shawver L, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576–578, 1994
Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM (1996) Dominant-negative inhibition of flk-1 suppresses the growth of many tumour types in vivo. Cancer Res 56: 1615–1620
Kendall RL, Thomas KA. Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90: 10705–10709, 1993
Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK. Flk-1 as a target for tumour growth inhibition. Cancer Research 56: 3540–3545, 1996
Saleh M, Stacker SA, Wilks AF (1996) Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56: 393–401
Cheng SY, Huang HJS, Nagane M, Ji XD, Wang DG, Shih CCY, Arap W, Huang CM, Cavenee WK (1996) Suppression of glioblastoma angiogenicity and tumourigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 93: 8502–8507
Claffey KP, Brown LF, Delaguila LF, Tognazzi K, Yeo KT, Manseau EJ, Dvorak HF (1996) Expression of vascular permeability factor vascular endothelial growth factor by melanoma cells increases tumour growth, angiogenesis, and experimental metastasis. Cancer Res 56: 172–181
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Plate, K.H. (1998). Control of Tumor Growth Via Inhibition of Tumor Angiogenesis. In: Walden, P., Trefzer, U., Sterry, W., Farzaneh, F., Zambon, P. (eds) Gene Therapy of Cancer. Advances in Experimental Medicine and Biology, vol 451. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5357-1_9
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5357-1_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7444-2
Online ISBN: 978-1-4615-5357-1
eBook Packages: Springer Book Archive